Coronavirus Disease 2019 in Children
Top Cited Papers
Open Access
- 28 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 9, 668484
- https://doi.org/10.3389/fped.2021.668484
Abstract
Since its appearance in Wuhan in mid-December 2019, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related 19 coronavirus disease (COVID-19) has spread dramatically worldwide. It soon became apparent that the incidence of pediatric COVID-19 was much lower than the adult form. Morbidity in children is characterized by a variable clinical presentation and course. Symptoms are similar to those of other acute respiratory viral infections, the upper airways being more affected than the lower airways. Thus far, over 90% of children who tested positive for the virus presented mild or moderate symptoms and signs. Most children were asymptomatic, and only a few cases were severe, unlike in the adult population. Deaths have been rare and occurred mainly in children with underlying morbidity. Factors as reduced angiotensin-converting enzyme receptor expression, increased activation of the interferon-related innate immune response, and trained immunity have been implicated in the relative resistance to COVID-19 in children, however the underlying pathogenesis and mechanism of action remain to be established. While at the pandemic outbreak, mild respiratory manifestations were the most frequently described symptoms in children, subsequent reports suggested that the clinical course of COVID-19 is more complex than initially thought. Thanks to the experience acquired in adults, the diagnosis of pediatric SARS-CoV-2 infection has improved with time. Data on the treatment of children are sparse, however, several antiviral trials are ongoing. The purpose of this narrative review is to summarize current understanding of pediatric SARS-CoV-2 infection and provide more accurate information for healthcare workers and improve the care of patients.This publication has 171 references indexed in Scilit:
- British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011Thorax, 2011
- Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin‐(1–7) or an angiotensin II receptor antagonistThe Journal of Pathology, 2011
- Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan PopulationClinical and Vaccine Immunology, 2008
- Seroepidemiology of group I human coronaviruses in childrenJournal of Clinical Virology, 2007
- Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in miceImmunology, 2007
- Severe Acute Respiratory Syndrome in ChildrenThe Pediatric Infectious Disease Journal, 2007
- Children's vaccines do not induce cross reactivity against SARS-CoVJournal of Clinical Pathology, 2006
- Age- and gender-related difference of ACE2 expression in rat lungLife Sciences, 2006
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology & Infection, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003